Abstract:ID 96214 Poster Board 484 Statement of the Problem . Epilepsy is the 4 th common neurological disorder after Parkinson's and Alzheimer's Disease and Stroke, with 3 million people in the US and 65 million people worldwide living with epilepsy. At the molecular level, it is known that voltage-gated sodium (VGSC) and calcium channels are related to the onset of seizures. Our lab engages in early drug design and discovery of novel small molecules as potential anti-seizure analogs, for epilepsy. Previous hit-to-lead optimization and target identification studies performed by our research team, led to the discovery of lead compound, ETSP 518001.This analog has been shown to act as a potent and selective Ca v 3.2 and Ca v 3.3 T-type voltage-gated calcium channel (T-VGCC) inhibitor. The objective of the work presented is to evaluate the inhibitory effects of several novel enaminone derivatives based on the prototype ETSP 518001 to identify new lead compounds as T-VGCC inhibitors. Methods: To design the novel enaminone derivatives, we utilized MedChem Studio, a simulation program to determine the druggability of the desired small molecules. Preliminary in vitro whole cell patch clamp experiments were performed to assess the inhibitory effects of several target analogs on voltage-activated Ca 2+ currents in human embryonic kidney (HEK-293) cells. Cav3.2 transfected HEK 293 cells were treated with 50 μM of test compounds and compared to the control group (none pretreated HEK 293 cells). Statistical analyses consisted of t-test for pairwise comparisons or one-way ANOVA followed by post hoc analysis using Tukey's honest significant difference test for comparisons between multiple groups. To validate the biological activity, studies were conducted at the National Institutes of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, NIH. ETSP 578001 was investigated in acute rodent seizure models, to determine the efficacy and safety as an anti-seizure agent. Results. Each enaminone analog in our novel series were examined in MedChem studio and were calculated to have an average CLogP value of 2.96, and predicted to have high blood brain barrier permeability (99%). Preliminary in vitro studies showed ETSP 578001 has ≥ 90% inhibition of T-VGCC current, generated by the Ca v 3.2 subunit. Enaminone analog RHB62 caused a reduction in the Ca 2+ current, with lower potency than ETSP 578001. No inhibitory effect was shown at a similar concentration for analogs RHB59, RHB95 or RHB103. Further research showed that ETSP 578001 analog also inhibited VGSCs and had no effect on cell viability. These results show that ETSP 578001 had dual inhibition properties. Results from the preclinical in vivo study demonstrated that compound ETSP 587001 had low efficacy in the 6Hz 44 mA and the maximal electroshock (MES) rodent seizure model, as 0/4 animals were protected at pretreatment times 0.5h and 2h. Conclusion: A target-based drug design strategy was employed, that led to the discovery of ETSP 578001, as a dual VGSC and T-VGCC blocker. This analog showed toxicity in the ETSP rodent seizure model. Future studies will involve lead optimization and target identification studies on ETSP 578001. PhRMA Foundation, Pre-Doctoral Fellowship in Drug Discovvery University of Maryland Eastern Shore Richard A. Bernstein Endowment

Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A

Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams

Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants

Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

Crystal Structure Of Botulinum Neurotoxin A2 In Complex With The Human Protein Receptor Sv2c Reveals Plasticity In Receptor Binding

Levetiracetam inhibits endocytosis and augments short-term depression

No Major Role of Common SV2A Variation for Predisposition or Levetiracetam Response in Epilepsy.

Levetiracetam: A New Antiepileptic Drug For The Adjunctive Therapy Of Chronic Epilepsy

Recognition of antiepileptic brivaracetam by synaptic vesicle protein 2A

Levetiracetam prevents Aβ42 production through SV2a-dependent modulation of App processing in Alzheimer's disease models

Dual-pocket Inhibition of Navchannels by the Antiepileptic Drug Lamotrigine

Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C

Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base

Single-dose Intravenous Administration of Antiepileptic Drugs Induces Rapid and Reversible Remodeling in the Brain: Evidence from a Voxel-Based Morphometry Evaluation of Valproate and Levetiracetam in Rhesus Monkeys

Effect of intranasal and oral administration of levetiracetam on the temporal and spatial distributions of SV2A in the KA‐induced rat model of SE

Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes

The Drug Design and Discovery of Novel Enaminone Derivatives as Potential Anti-seizure Agents

A brief review on efficacy and safety of brivaracetam in the management of partial onset epilepsy

Brivaracetam Modulates Short-Term Synaptic Activity and Low-Frequency Spontaneous Brain Activity by Delaying Synaptic Vesicle Recycling in Two Distinct Rodent Models of Epileptic Seizures

Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Tuning Sodium Channel Blockers to the Near-Atomic Level